CASI Pharmaceuticals (FRA:ENM) Cyclically Adjusted Book per Share: €8.68 (As of Dec. 2025)


FRA:ENM CASI Pharmaceuticals Inc FRA:ENM
29 GF Score
Price €1.54
GF Value €11.74
! 5 Warning Signs
View Full Analysis

What is CASI Pharmaceuticals Cyclically Adjusted Book per Share?

CASI Pharmaceuticals FRA:ENM 29 Cyclically Adjusted Book per Share is €8.68 as of Dec. 2025. GuruFocus rates FRA:ENM with a GF Score™ of 29/100 and a GF Value™ of €11.74. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

CASI Pharmaceuticals's adjusted book value per share for the three months ended in Dec. 2025 was €-1.549. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €8.68 for the trailing ten years ended in Dec. 2025.

During the past 12 months, CASI Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 1.10% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -4.20% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -1.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of CASI Pharmaceuticals was 35.50% per year. The lowest was -53.60% per year. And the median was -18.60% per year.

As of today (2026-07-06), CASI Pharmaceuticals's current stock price is €1.54. CASI Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2025 was €8.68. CASI Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 0.18.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of CASI Pharmaceuticals was 10.56. The lowest was 0.02. And the median was 1.25.


CASI Pharmaceuticals  (FRA:ENM) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

CASI Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.54/8.68
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of CASI Pharmaceuticals was 10.56. The lowest was 0.02. And the median was 1.25.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


CASI Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


CASI Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for CASI Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CASI Pharmaceuticals Cyclically Adjusted Book per Share Chart

CASI Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.61 4.87 1.07 2.58 8.68

CASI Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.58 3.39 6.19 4.43 8.68

FRA:ENM vs ITRMF, OGEN, AZTR: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, CASI Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CASI Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where CASI Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


FRA:ENM
29GF Score
CASI Pharmaceuticals Inc FRA:ENM
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CASI Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, CASI Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Dec. 2025 was:

Adj_Book= Book Value per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=-1.549/115.8300*115.8300
=-1.549

Current CPI (Dec. 2025) = 115.8300.

CASI Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201603 0.978 102.200 1.108
201606 1.879 101.400 2.146
201609 2.886 102.400 3.265
201612 3.273 102.600 3.695
201703 2.988 103.200 3.354
201706 2.517 103.100 2.828
201709 2.171 104.100 2.416
201712 4.664 104.500 5.170
201803 6.886 105.300 7.575
201806 8.264 104.900 9.125
201809 10.398 106.600 11.298
201812 10.097 106.500 10.982
201903 9.634 107.700 10.361
201906 8.232 107.700 8.853
201909 7.575 109.800 7.991
201912 6.719 111.200 6.999
202003 6.310 112.300 6.508
202006 5.573 110.400 5.847
202009 6.270 111.700 6.502
202012 5.408 111.500 5.618
202103 6.011 112.662 6.180
202106 5.628 111.769 5.832
202109 5.266 112.215 5.436
202112 5.349 113.108 5.478
202203 5.004 114.335 5.069
202206 4.654 114.558 4.706
202209 4.581 115.339 4.601
202212 3.127 115.116 3.146
202303 2.775 115.116 2.792
202306 2.233 114.558 2.258
202309 2.017 115.339 2.026
202312 1.656 114.781 1.671
202403 1.062 115.227 1.068
202406 0.580 114.781 0.585
202409 0.807 115.785 0.807
202412 0.114 114.893 0.115
202503 -0.482 115.116 -0.485
202506 -1.137 114.907 -1.146
202509 -1.186 115.470 -1.190
202512 -1.549 115.830 -1.549

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €8.68 mean?
CASI Pharmaceuticals (FRA:ENM) has a Cyclically Adjusted Book per Share of €8.68 as of Dec. 2025. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on CASI Pharmaceuticals and its competitors.
Is CASI Pharmaceuticals' Cyclically Adjusted Book per Share too high?
CASI Pharmaceuticals' current Cyclically Adjusted Book per Share is €8.68. Overall, CASI Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does CASI Pharmaceuticals' Cyclically Adjusted Book per Share compare to ITRMF and OGEN?
CASI Pharmaceuticals' Cyclically Adjusted Book per Share of €8.68 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on CASI Pharmaceuticals and its competitors. CASI Pharmaceuticals's current Cyclically Adjusted Book per Share is €8.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CASI Pharmaceuticals stock overvalued right now?
CASI Pharmaceuticals (FRA:ENM) has a current Cyclically Adjusted Book per Share of €8.68. The stock's GF Value™ is €11.74, compared to a current price of €1.54 — trading 86.9% below its estimated fair value. The current Cyclically Adjusted Book per Share is €8.68. CASI Pharmaceuticals' overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For CASI Pharmaceuticals (FRA:ENM), the current Cyclically Adjusted Book per Share is €8.68 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CASI Pharmaceuticals (FRA:ENM) Overvalued in 2026?

Based on GuruFocus' analysis, CASI Pharmaceuticals stock appears to be undervalued. The current stock price of €1.54 is trading 86.9% below its estimated GF Value™ of €11.74.

Key valuation signals for FRA:ENM:

  • Cyclically Adjusted Book per Share: €8.68
  • GF Value™: €11.74 vs. price of €1.54 (86.9% below fair value)
  • GF Score™: 29/100 with 5 warning signs

No single metric tells the full story. See the FRA:ENM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CASI Pharmaceuticals Business Description

Other Exchanges CASIF:USA
Address Jianguo Road, No. 81, Room 1701-1702, China Central Office Tower 1, Huamao Office Building, Chaoyang District, Beijing, CHN, 100025
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
29GF Score

Get the complete analysis for FRA:ENM

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.54
Price
€11.74
GF Value